Market Research Logo

The World Market for Anti-Infectives, Volume I: Antifungals

In the past 100 years, there has been a steady increase in the incidence of serious secondary systemic fungal infections. One of the factors aiding the spread of fungal disease has been the widespread use of broad-spectrum antibiotics, which eliminate or decrease the non-pathogenic bacterial populations that normally compete with fungi. Another has been the vast increase in populations with with compromised immune response (caused by AIDS or by the action of immunosuppressant drugs or cancer chemotherapy agents).

In addition to rising prevalence, new technology in anti-fungal agent discovery has been brisk and innovative approaches have made anti-fungal drug development a diverse and competitive field.

This volume of Kalorama Information’s completely updated series on the World Market for Anti-Infectives focuses on two segments of anti-fungal treatment: systemic and topical. The report covers both currently marketed and late stage development anti-fungal products in detail.

The report includes statistical information for fungal infections by type worldwide, with special emphasis on the U.S. market. The market segments provide an overview, description of products on the market, description of products in development, market estimates and forecasts, and competitive analysis of leading providers. The report also includes current issues and trends affecting the industry.

Revenues for each segment were generated using dollar and unit sales for each product. All market data pertain to the world market at the manufacturers’ level. The base year for data was 2004. Historical data are provided for the years 2002 and 2003, with forecast data provided for 2005 through 2009. Compound annual growth rates (CAGRs) are provided for the 2002-2004, 2004-2009, and 2002-2009 periods for each industry segment covered. Competitive analysis is provided for the year 2004. The forecasted market analysis for 2005-2009 was based on probability of approval and sales of products in late stage development, product marketing, and demographic trends.

The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.


Chapter One: Executive Summary

  • Introduction
  • Scope and Methodology
  • Size and Growth of the Market
  • Issues and Trends Affecting the Market
  • Leading Competitors

Chapter Two: Introduction

  • Fungal Infections
    • Superficial
    • Systemic
      • Histoplasmosis
      • Coccidioidomycosis
      • Blastomycosis

  • Demographics and Statistics

Chapter Three: Systemic Antifungal Drug

  • Overview:
  • Description of Products
    • Allylamines
      • Terbinafine (Lamisil, Novartis)

    • Azoles
      • Fluconazole (Diflucan, Pfizer)
      • Ketoconazole (Nizoral, Johnson & Johnson)
      • Miconazole (Monistat, Johnson & Johnson)
      • Itraconazole (Sporanox, Johnson & Johnson)

    • Polyene Macrolides
      • Amphotericin B
      • Nystatin (Mycostatin, Westwood Squibb)
      • Griseofluvin (Fulvicin, Schering)

    • Miscellaneous Antifungals
      • Flucytosine (Ancobon, ICN)
      • Echinocandins
      • Caspofungin (Cancidas for Injection, Merck)

  • Research and Development
  • Market Size and Growth
  • Competitive Analysis

Chapter Four: Topical Antifungal Drugs

  • Overview
  • Description of Products
    • Allylamines
      • Naftifine (Naftin, Allergan)
      • Terbinafine (Lamisil, Novartis)
      • Butenafine (Mentax, Bertek)
      • Azoles
        • Miconazole (Monistat-Derm, OrthoDermatological)
        • Clotrimazole (Mycelex, Bayer; Lotrimin, Schering)
        • Ketoconazole (Nizoral, J&J)
        • Oxiconazole (Oxistat, GlaxoSmithKline/Elan)
        • Econazole (Spectazole, Ortho Dermatological)
        • Sulconazole (Exelderm, Westwood-Squibb)
        • Terconazole (Terazol, Ortho Dermatological)
        • Polyene Macrolides
          • Nystatin (Mycostatin, Westwood Squibb)
          • Miscellaneous Antifungals
            • Ciclopirox (Penlac, Sanofi-Aventis/Dermik)
            • Selenium sulfide (Selsun, Ross)
            • Tolnaftate (Tinactin, Alpharma)
            • Amorolfine (Loceryl, Roche)

        • Research and Development
        • Market Size and Growth
        • Competitive Analysis

Chapter Five: Issues and Trends

  • Expanded Use of Azoles
  • Drug Resistance and Interactions
  • Standardized Susceptibility Testing
  • Generic Impact and Availability
  • Importance of Drug Delivery
  • Fungal Vaccine Development
  • Rx-to-OTC Switches
  • Antifungal Proteins
  • Addressing the Unmet Need of the Antifungal Treatment Market
  • Tarmogen Technology

Chapter Six: Market Summary

  • Total Market Size and Forecast

chapter Seven: Company Profiles

  • Introduction
  • Bayer AG
  • Dermik Laboratories, Inc.
  • Enzon Pharmaceuticals, Inc.
  • Fujisawa Pharmaceutical Company, Ltd.
  • Johnson & Johnson Group
  • Merck & Company, Inc.
  • Novartis Pharmaceuticals Corporation
  • Pfizer, Inc.
  • Schering-Plough Corporation

Appendix: Company Directory
List of Exhibits
Chapter One: Executive Summary

  • Table 1-1: The Total World Market for Antifungal Drugs 2002-2009
  • Figure 1-1: The World Market for Antifungal Drugs 2002-2009

Chapter Two: Introduction

  • Table 2-1: Estimated World and U.S. Incidence of Fungal Infections
  • Figure 2-1: Estimated World and U.S. Incidence of Leading Fungal Infections
  • Table 2-2: World Population by Selected Geographical Region, 2004-2050
  • Figure 2-2: World Population by Selected Geographical Region, 2003-2050
  • Table 2-3: Estimated World Population by Age and Geographical Region, 2004
  • Figure 2-3: Estimated World Population by Age and Geographical Region, 2004

Chapter Three: Systemic Antifungal Drug

  • Table 3-1: Currently Available Systemic Antifungal Agents (Type, Brand, and Manufacturer)
  • Table 3-2: Systemic Antifungal Drugs in Development
  • Table 3-3: The Market for Systemic Antifungal Drugs 2002-2009
  • Figure 3-1: Systemic Antifungal Drug Market 2002-2009
  • Table 3-4: Systemic Antifungal Drug Market by Product Type (Allylamines, Azoles, Polyene Macrolides, and Others) 2002-2009
  • Figure 3-2: Systemic Antifungal Drug Market Revenues and Distribution by Product Type, 2002-2009
  • Figure 3-3: Systemic Antifungal Drug Market Share of Revenues by Product Type 2002-2009
  • Figure 3-4: Systemic Antifungal Drug Market Share by Product Type 2004 and 2009
  • Table 3-5: Systemic Antifungal Drug Market Estimated Products Sales by Infection Type, 2004
  • Figure 3-5: Systemic Antifungal Drug Market Market Share by Infection Type, 2004
  • Table 3-6: Systemic Antifungal Drug Market Estimated Products Sales by Geographic Region, 2004
  • Figure 3-6: Systemic Antifungal Drug Market Market Share by Geographic Region, 2004
  • Table 3-7: Systemic Antifungal Drug Market Estimated Revenues and Market Share of Leading Suppliers 2004
  • Figure 3-7: Systemic Antifungal Drug Market Estimated Market Share by Leading Suppliers 2004
  • Table 3-8: Systemic Antifungal Drug Market Estimated Sales of Top Antifungal Products 2004
  • Figure 3-8: Systemic Antifungal Drug Market Estimated Market Share of Top Antifungal Products, 2004

Chapter Four: Topical Antifungal Drugs

  • Table 4-1: Currently Available Topical Antifungal Agents (Type, Brand, and Manufacturer)
  • Table 4-2: Topical Antifungal Drugs in Development
  • Table 4-3: The Market for Topical Antifungal Drugs 2002-2009
  • Figure 4-1: Topical Antifungal Drug Market 2002-2009
  • Table 4-4: Topical Antifungal Drug Market by Product Type (Allylamines, Azoles, Polyene Macrolides, and Others) 2002-2009
  • Figure 4-2: Topical Antifungal Drug Market Revenues and Distribution by Product Type 2002-2009
  • Figure 4-3: Topical Antifungal Drug Market Share of Revenues by Product Type 2002-2009
  • Figure 4-4: Topical Antifungal Drug Market Share by Product Type 2004 and 2009
  • Table 4-5: Topical Antifungal Drug Market Estimated Products Sales by Infection Type, 2004
  • Figure 4-5: Topical Antifungal Drug Market Market Share by Infection Type, 2004
  • Table 4-6: Topical Antifungal Drug Market Estimated Products Sales by Geographic Region, 2004
  • Figure 4-6: Topical Antifungal Drug Market Market Share by Geographic Region, 2004
  • Table 4-7: Topical Antifungal Drug Market Estimated Revenues and Market Share of Leading Suppliers 2004
  • Figure 4-7: Topical Antifungal Drug Market Estimated Market Share by Leading Suppliers 2004
  • Table 4-8: Topical Antifungal Drug Market Estimated Sales of Top Antifungal Products 2004
  • Figure 4-8: Topical Systemic Antifungal Drug Market
  • Estimated Market Share of Top Antifungal Products, 2004

Chapter Five: Issues and Trends

  • Table 5-1: Selected Antifungal Rx-to-OTC Switches
  • Table 5-2: Selected Potential Prescription Dermatological Rx-to-OTC Switches

Chapter Six: Market Summary

  • Table 6-1: The World Market for Antifungal Drugs 2002-2009
  • Figure 6-1: The World Market for Antifungal Drugs 2002-2009
  • Table 6-2: Topical Antifungal Drug Market by Type (Topical vs Systemic) 2002-2009
  • Figure 6-2: The World Market for Antifungal Drugs Revenues by Type (Systemic vs Topical) 2002-2009

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report